Glaucoma Vision Act of 2026
- Sponsor
- Rep. Wilson, Frederica S. [D-FL-24]
- Committees
- Oversight and Government Reform Committee (primary)
- Last action
- Sep 16, 2026
Bottom line
The Glaucoma Vision Act of 2026 expands access to annual glaucoma screenings for high-risk populations across major health insurance programs and funds public health initiatives and research to combat vision loss from glaucoma.
What it actually does
This bill mandates annual glaucoma screenings for high-risk individuals under private insurance, Medicare, Medicaid, and Federal Employees Health Benefits (FEHB) plans, requiring coverage without cost-sharing. It also establishes a Glaucoma Detection and Prevention Program at the CDC to provide free or low-cost screenings and follow-up treatment to uninsured and underinsured high-risk individuals, and authorizes grants for glaucoma and optic nerve damage research through the National Eye Institute.
Proponents argue
Proponents argue that early detection and treatment of glaucoma are crucial for preventing irreversible vision loss and blindness, especially among high-risk populations who are disproportionately affected. Expanding screening coverage and funding prevention programs will reduce long-term healthcare costs associated with advanced glaucoma and improve health equity by reaching underserved communities.
Opponents contend
While direct opposition to glaucoma screening is unlikely, potential concerns from critics might revolve around the increased financial burden on health plans and federal programs, the administrative complexity of implementing new mandates across multiple insurance types, or questions about the cost-effectiveness of universal annual screenings for all specified high-risk groups versus more targeted approaches.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its core provisions within a reasonable timeframe.
Section 3(a)
Mandated Glaucoma Screening Coverage for Private Insurance
This provision amends the Public Health Service Act to require private health plans to cover annual glaucoma screenings for "specified individuals" without imposing any cost-sharing (such as deductibles, copayments, or coinsurance). This mandate will apply to plan years beginning on or after January 1, 2027. "Specified individuals" include those 40 years of age or older who identify as having African, Hispanic/Latino, or Asian ancestry, or who have clinical risk factors for glaucoma, as well as all individuals 60 years of age or older.
Supporters argue
Proponents argue this provision ensures equitable access to crucial preventative eye care for high-risk populations, which can significantly reduce the incidence of irreversible vision loss and associated long-term healthcare costs.
Critics contend
Critics may contend that mandating new coverage without cost-sharing for private plans could lead to increased premiums for all enrollees, potentially making health insurance less affordable.
Tradeoffs
The provision balances the public health benefit of widespread preventative care for high-risk groups against the potential for increased costs within the private health insurance market.
Section 3(b)
Enhanced Medicare Coverage for Glaucoma Screenings
This provision amends the Social Security Act to eliminate cost-sharing for glaucoma screenings furnished to "specified individuals" under Medicare Part B. Currently, Medicare covers one glaucoma screening every 12 months for certain high-risk individuals, but this amendment ensures that these screenings are fully covered without deductibles or coinsurance for the broader definition of "specified individuals." These changes will apply to items and services furnished on or after January 1, 2027.
Section 3(c)
Mandatory Medicaid Coverage and No Cost-Sharing for Glaucoma Screenings
This provision amends the Social Security Act to make annual glaucoma screenings for "specified individuals" a mandatory benefit under Medicaid. It explicitly prohibits states from imposing any deduction, cost-sharing, or similar charge for these screenings. Furthermore, it ensures that alternative benefit plans offered through Medicaid must also include this coverage without cost-sharing. These changes will apply to medical assistance furnished on or after January 1, 2027.
Section 3(d)
Glaucoma Screening Coverage for Federal Employees Health Benefits
This provision amends Title 5 of the U.S. Code to require all Federal Employees Health Benefits (FEHB) plans to provide coverage for annual glaucoma screenings for "specified individuals." Crucially, it mandates that these screenings be covered without the imposition of any cost-sharing, including coinsurance, copayments, and deductibles. This amendment will apply to contracts entered into for plan years beginning on or after January 1, 2027.
Section 4
CDC Glaucoma Detection and Prevention Program
This section directs the Director of the Centers for Disease Control and Prevention (CDC), through the Vision Health Initiative, to expand and support glaucoma detection and prevention activities. It authorizes the CDC to award competitive grants to eligible entities, such as states, local health departments, community health centers, and nonprofit organizations. These grants are intended to provide free or low-cost glaucoma screenings and follow-up treatment to uninsured and underinsured high-risk individuals, with a priority for racial and ethnic minority communities. The section authorizes $10,000,000 for fiscal years 2027 through 2028 to carry out this program.
Section 5
National Eye Institute Glaucoma and Optic Nerve Damage Research Grants
This section amends the Public Health Service Act to authorize the Director of the National Eye Institute (part of NIH) to award competitive grants for research specifically related to glaucoma and optic nerve damage. The research areas include optic nerve regeneration and repair, neuroprotection strategies to prevent retinal ganglion cell loss, gene therapies targeting glaucoma-related pathways, and stem cell-based therapies. The provision authorizes $10,000,000 for fiscal years 2027 through 2028 to fund this research.
The bill defines "specified individual" as any individual 40 years of age or older who identifies as having African, Hispanic/Latino, or Asian ancestry, or has a clinical risk factor for glaucoma (including diabetes, a family history of glaucoma, elevated intraocular pressure, very low or very high blood pressure, myopia, a history of corneal refractive surgery or other causes of reduced central corneal thickness, or a history of chronic corticosteroid use). Additionally, any individual 60 years of age or older is considered a "specified individual" regardless of other factors.
Section 3(a)(5) and 3(d)
Why it matters:This is standard legislative practice to define terms once and then reference them consistently across different sections of law, ensuring uniformity.
Case for: Proponents argue that providing a clear, consistent, and comprehensive definition of eligibility ensures that high-risk populations are targeted for preventative screenings across all covered insurance programs, promoting health equity.
Case against: Critics might argue that the broad inclusion of "An individual 60 years of age or older" without further risk stratification could lead to a significant increase in screenings for lower-risk individuals within that age group, potentially increasing costs without a proportional benefit in early detection.
Estimated impact: This definition significantly expands the pool of individuals eligible for no-cost annual glaucoma screenings across all major insurance types, potentially affecting millions of Americans.
The bill defines "glaucoma" by cross-referencing an existing definition in federal law: "glaucoma (as defined in section 1861(uu) of the Social Security Act)". This means the medical definition of glaucoma used for coverage purposes is consistent with established federal health law.
Section 3(a)(5), 3(c)(1)(C), 3(c)(3), 3(c)(4)(A)(iii), 3(c)(4)(B)(xv), 3(d)(1)
Why it matters:This is standard legislative practice to avoid redefining terms that are already established in existing statutes, ensuring consistency and avoiding potential conflicts with current law.
Case for: Proponents argue that referencing an established definition ensures consistency with existing federal health law and medical standards for glaucoma diagnosis, avoiding ambiguity and facilitating implementation.
Case against: Critics might suggest that requiring an external lookup for a core definition can hinder immediate understanding for a lay reader or even for some healthcare administrators unfamiliar with that specific statutory reference.
Estimated impact: Ensures that the medical condition for which screenings are mandated aligns with a federally recognized and consistent definition, impacting how diagnoses are made and covered.